Module 2 du bio-incubateur de l’ESBS, Pôle API.
300 Boulevard Sébastien Brant, CS 10413
About DynacureDynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dynacure’s Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery.
CEO: Stéphane Van Rooijen
COO: Frédéric Legros
Head of Development: Dr Leen Thielemans
Scientific Advisor: Belinda Cowling
Scientific Advisor: Scientific Advisor:
Please click here for Dynacure's products.
22 articles with Dynacure
11/9/2017Ionis earns $5 million license fee from Dynacure.